Maurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.
Maurie Markman, MD, CTCA
Advertisement
Articles by Maurie Markman, MD, CTCA
It is difficult to browse a major medical journal these days and not find an article, commentary, or editorial that discusses the objectively rather profound implications for clinical science and health care delivery resulting from simply stunning advances in computer technology in the arena of artificial intelligence.
Advertisement
Latest Updated Articles
Dr Markman on the Role of PARP Inhibitors in Ovarian CancerPublished: November 24th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5